Jazz Pharmaceuticals Plc · NASDAQ:JAZZ
Jazz Pharmaceuticals — 44th Annual J.P. Morgan Healthcare Conference (January 2026)
18 slides from Jazz Pharmaceuticals's conference presentation, January 2026
Slide 1: J.P. Morgan Healthcare Conference: Redefining Possibilities in Rare Disease
January 2026 44th Annual J.P. Morgan Healthcare Conference Redefining Possibilities in Rare Disease Renee Gala, President & CEO
Slide 2: Caution Concerning Forward-Looking Statements
Transforming Lives. Redefining Possibilities. Caution Concerning Forward-Looking Statements This presentation contains forward-looking statements and financial targets, including, but not limited to, statements related to: the Company’s growth prospects and future financial and operating results, in
Slide 3: Strong Momentum from an Outstanding 2025
Strong Momentum from an Outstanding 2025 Research and Commercial Corporate Corporate Development Development Rapid approval1 / launch exceeding expectations Settled outstanding ANDA litigation = Acquisition Practice-changing 1L GEA data durability into the very-late 2030’s derisks $2B+ opportunity A
Slide 4: Our Evolution as a Successful Rare Disease Company
Our Evolution as a Successful Rare Disease Company 2026 and Beyond Deepen and expand commitment 2014 - 2025 to rare disease 2003 - 2013 Leverage and strengthen key Over $4B in revenue capabilities built over 20+ years ~$900M in revenue Diversified revenue base with concentrated on Xyrem three $1B+ f
Slide 5: Playing to Jazz's Strategic Advantages
Refined Strategic Focus on Rare Disease Playing to Jazz’s Strategic Advantages RARE RARE RARE NEW RARE ONCOLOGY EPILEPSY SLEEP THERAPEUTIC AREAS January 2026 l 5
Slide 6: Refined Strategic Focus on Rare Disease
Refined Strategic Focus on Rare Disease Attractive Growth Market That Plays to Jazz’s Strengths Rare Disease High unmet need Small patient populations RARE RARE RARE NEW RARE ONCOLOGY EPILEPSY SLEEP THERAPEUTIC Concentrated call points AREAS Differentiated support services Lower competitive intensit
Slide 7: How Jazz Will Compete in Rare Disease
How Jazz Will Compete in Rare Disease Leveraging Expertise to Optimize Future Investments and Growth • Focus on areas of significant unmet need • Pursue innovative products with potential to be standards of care • Prepared to assume greater clinical risk within areas of existing expertise • Build $1
Slide 8: Track Record of Success in Rare Disease
Track Record of Success in Rare Disease Research and Commercial Corporate Development Development $2B+ opportunity Multiple $1B+ $500M+ peak potential that is a cornerstone drugs in 20251 outperforming initial of our future growth expectations 1Based on 2025 net product sales for Epidiolex and Xywav
Slide 9: Zanidatamab: High Value, De-Risked Asset with Broad Potential Across Indications
RESEARCH AND DEVELOPMENT COMMERCIAL CORPORATE DEVELOPMENT Zanidatamab: High Value, De-Risked Asset with Broad Potential Across Indications Zanidatamab is a highly active, differentiated HER2-targeted bispecific mAb with compelling survival data Novel and Best-in-Class Compelling $2B+ Differentiated
Slide 10: Positive Phase 3 Data Support Zanidatamab as 1L HER2+ GEA Standard of Care
RESEARCH AND DEVELOPMENT COMMERCIAL CORPORATE DEVELOPMENT Positive Phase 3 Data Support Zanidatamab as 1L HER2+ GEA Standard of Care ‘‘ The results of the HERIZON-GEA-01 study are practice-changing. In addition to the PFS and OS benefits, the remarkably long duration of response and consistent benef
Slide 11: Progress Towards Realizing Full Potential of Zanidatamab
RESEARCH AND DEVELOPMENT COMMERCIAL CORPORATE DEVELOPMENT Progress Towards Realizing Full Potential of Zanidatamab 2026 2027 and Beyond • Continued execution to realize full value of zanidatamab across indications • Expect to realize full value with multiple indication expansion opportunities: GEA •
Slide 12: Driving Durable Growth Through Strong Commercial Execution: Epidiolex and Xywav
RESEARCH AND DEVELOPMENT COMMERCIAL CORPORATE DEVELOPMENT Driving Durable Growth Through Strong Commercial Execution Epidiolex Xywav Standard of care in LGS, DS, and TSC Differentiated low-sodium oxybate ✓ Strong commercial execution achieving ✓ Focused on continued commercial execution $1B+ in sale
Slide 13: Enhancing Value Through Acquisition of Chimerix
RESEARCH AND DEVELOPMENT COMMERCIAL CORPORATE DEVELOPMENT Enhancing Value Through Acquisition of Chimerix 2025 2026 and Beyond • Successfully acquired and integrated Chimerix Phase 3 ACTION Trial • Modeyso approval granted ahead of schedule • Enrollment ongoing and on track; interim OS data • Strong
Slide 14: Well Positioned to Succeed in Rare Disease
Well Positioned to Succeed in Rare Disease Research and Commercial Corporate Development Development Strong Financial $4B+ $1B+ $2B+ Position Total revenues in 20251 Cash from operations2 Cash, cash equivalents, and investments3 1Jazz Pharmaceuticals plc has not finalized its financial results for t
Slide 15: Strong Momentum Into 2026
Strong Momentum Into 2026 Research and Commercial Corporate Development Development Zanidatamab sBLA submission for 1L GEA in 1H26 Full-year commercial sales Potential approval in 1L GEA Identifying and late 2026 pursuing opportunities EmpowHER-BC-303 trial top-line in Rare Disease to drive readout
Slide 16: Thank You
Jazz Pharmaceuticals. THANK YOU
Slide 17: Q&A
Jazz Pharmaceuticals. Q&A
Slide 18: Glossary
Glossary Acronym Definition Acronym Definition 1H26 first half 2026 IH Idiopathic Hypersomnia 1L First-line IP Intellectual property 1LM First-line maintenance LGS Lennox-Gastaut syndrome AI Artificial intelligence M million ASCO American Society of Clinical Oncology mAb Monoclonal antibody ANDA Abb
Jazz Pharmaceuticals — 44th Annual J.P. Morgan Healthcare Conference (January 2026) on 6ix